Leukemia

Findings from a phase 3 trial demonstrated that half of patients with FLT3-ITD-mutant acute myeloid leukemia and detectable minimal residual risk derived a relapse-free survival benefit with Xospata.

Lasting guilt gets no one anywhere — especially when it comes to cancer.

The CAR-T cell therapy, Tecartus, improved outcomes for patients with B-cell acute lymphoblastic leukemia, offering a promising standard of care for this patient population.

Three-fourths of patients with relapsed/refractory B-cell acute lymphoblastic leukemia experienced complete responses — which tended to be durable — when treated with the CAR-T cell therapy, Obe-cel.

From a teen cancer survivor being gifted tickets to Taylor Swift’s ‘Eras’ tour to Michael Hendry backing out of the US Open due to a leukemia diagnosis, here’s what’s happening in the oncology space this week.

Cryopreserved stem cells led to a higher rate of relapse in patients with blood cancer, though there was no difference in survival, research showed.

Lori A. Leslie, MD, and Hoshiyuki Iida, APN, offer closing thoughts on the future treatment landscape of chronic lymphocytic leukemia.

Experts on chronic lymphocytic leukemia discuss how to approach cost considerations and available resources for CLL treatments.

Insights on supportive care and approaches to managing adverse effects of BTK inhibitors in the treatment of chronic lymphocytic leukemia.

Bariatric surgery may reduce the body’s way of absorbing drugs for chronic myeloid leukemia, research showed.

Omisirge is an umbilical cord blood-based therapy that may prevent infection in patients with blood cancer undergoing stem cell transplant.

CLL expert Lori A. Leslie, MD, gives a comprehensive overview of the ALPINE and ELEVATE-RR head-to-head studies of BTK inhibitors in CLL.

Lori A. Leslie, MD, an expert on CLL, talks about factors that influence treatment decisions.

After leaving the hospital, I craved the security and support my cancer care team provided me.

CLL experts offer insights on shared decision-making with patients while selecting treatments.

Lori A. Leslie, MD, an expert on chronic lymphocytic leukemia, provides a comprehensive overview of BTK inhibitors used in the treatment of CLL.

Hoshiyuki Iida, APN, discusses his role in the multidisciplinary team in the treatment of patients with chronic lymphocytic leukemia.

Lori A. Leslie, MD, and Hoshiyuki Iida, APN, provide an overview of chronic lymphocytic leukemia and the risk stratification process.

After going through cancer, I better recognize my triggers for heightened anxiety.

Even after my son survived cancer, I still had fears — and nightmares — of the worst.

Regarding overall survival, allogeneic HCT did not have a benefit over consolidation chemotherapy in patients with intermediate-risk disease.

After undergoing a bone marrow transplant for my leukemia, I started to have some odd symptoms, and sent wacky texts to my loved ones.

This updated administration of Udenyca allows patients to receive this treatment in the office or at home.

Experts are concerned that the train derailment in Ohio may pose cancer risks down the line.

Karen Estrada was shocked when she was diagnosed with leukemia and ended up on a lifesaving clinical trial, although her journey was not entirely smooth.

When I was undergoing cancer treatment, writing was a creative outlet that helped calm my nerves.

Researchers conducting a phase 2 trial recently dosed the first patients with a novel menin inhibitor for the treatment of patients with NPM1-mutant relapsed or refractory acute myeloid leukemia.

Overall survival results were durable for patients with relapsed/refractory b-cell acute lymphoblastic leukemia when treated with CAR-T cell therapy, Tecartus.

Two experts explain what patients need to know about the recent approval of Brukinsa for patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

After being diagnosed with leukemia, my Golden Retriever, Payton, was my emotional caregiver and gave me the will to live.